Would you offer live vaccines (e.g., MMRV / measles) to patients on bispecific antibodies for multiple myeloma?  

This comes up from time to time, but especially in 2025 with the multistate outbreaks and the rising adoption of bispecific antibodies (e.g., teclistamab, talquetamab, elranatamab) for multiple myeloma. Would you ever consider live vaccines? If so, what parameters would you set? E.g., CD4 counts, interval between bispecific doses, presence/absence of IVIG?